Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Long-term safety and efficacy of single-agent lbrutinib in patients with relapsed or refractory mantle cell lymphoma: Updated results of an international, multicenter, open-label phase 2 study Dreyling, M., Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, J., Stilgenbauer, S., Jedrzejczak, W. W., Johnson, P., Spurgeon, S. E., Zhang, L., Baher, L., Cheng, M., Beaupre, D. M., Blum, K. A. KARGER. 2015: 18–19
View details for Web of Science ID 000364268800038